Breaking News Instant updates and real-time market news.

AGLE

Aeglea BioTherapeutics

$8.60

-0.23 (-2.60%)

07:17
03/13/18
03/13
07:17
03/13/18
07:17

Aeglea BioTherapeutics reports repeat dose data from Phase 1/2 trial of AEB1102

Aeglea BioTherapeutics reported new repeat dose data from its Phase 1/2 open-label trial of pegzilarginase in patients with Arginase 1 Deficiency. Aeglea presented repeat dose data from the Phase 1/2 clinical trial of pegzilarginase for two adult patients and single ascending dose data for one pediatric patient with Arginase 1 Deficiency at the 2018 Society for Inherited Metabolic Disorders Annual Meeting on March 12, 2018. Sustained lowering of plasma arginine was achieved with repeated weekly IV dose of 0.04 mg/kg of pegzilarginase. Arginine-derived metabolites elevated at baseline were rapidly decreased and reductions maintained with repeat doses of pegzilarginase. Pegzilarginase was well tolerated with the exception of a single infusion-associated reaction in one pediatric patient who had anti-drug antibodies and blunting of the expected reduction in plasma arginine after the second dose. The patient transitioned to the repeat dose part of the trial and received three further infusions. Although dosing was well tolerated with premedication and slower infusion rates, the patient withdrew consent due to the burden of balancing school and the clinical trial. No marked or sustained increase in ADA titers were seen in the two adult Arginase 1 Deficiency patients or in the 48 cancer patients tested after dosing with pegzilarginase. Baseline ADA at low titer was detected in one of two adult Arginase 1 Deficiency patients and four of 48 cancer patients. There was no apparent effect of the presence of the ADA on arginine reduction or safety profile. The effects of repeat dosing of pegzilarginase provides an opportunity to evaluate the clinical benefits of sustained reduction of plasma arginine beyond what can be achieved with standard of care therapy. The Company expects to report pediatric and adult repeat dose data in patients with Arginase 1 Deficiency in the third quarter of 2018. The first uveal and cutaneous melanoma patients were dosed with pegzilarginase in Aeglea's open-label Phase 1 cohort expansions, with the intent to confirm the safety profile and Phase 2 dose and identify further signals of clinical activity. The Company expects to report Phase 1 cohort expansion topline data, including safety and clinical activity, in the fourth quarter of 2018.

  • 13

    Mar

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,629.19

-71.31 (-4.19%)

06:26
12/10/18
12/10
06:26
12/10/18
06:26
Periodicals
Amazon dismisses workers in U.S., India over data leak, WSJ reports »

Amazon has dismissed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RF

Regions Financial

$14.90

-0.4 (-2.61%)

06:26
12/10/18
12/10
06:26
12/10/18
06:26
Downgrade
Regions Financial rating change  »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VC

Visteon

$67.58

-4.1 (-5.72%)

, F

Ford

$8.82

-0.205 (-2.27%)

06:24
12/10/18
12/10
06:24
12/10/18
06:24
Downgrade
Visteon, Ford rating change  »

Goldman downgrades…

VC

Visteon

$67.58

-4.1 (-5.72%)

F

Ford

$8.82

-0.205 (-2.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

FBHS

Fortune Brands

$42.60

0.07 (0.16%)

06:23
12/10/18
12/10
06:23
12/10/18
06:23
Upgrade
Fortune Brands rating change  »

Fortune Brands upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$137.42

-2.14 (-1.53%)

06:22
12/10/18
12/10
06:22
12/10/18
06:22
Periodicals
Facebook building hardware prototype testing facility in New Mexico, BI reports »

Facebook is building a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAAS

AquaVenture

$18.09

0.26 (1.46%)

06:21
12/10/18
12/10
06:21
12/10/18
06:21
Conference/Events
AquaVenture management to meet with B.Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

WRK

WestRock

$45.33

-0.875 (-1.89%)

06:20
12/10/18
12/10
06:20
12/10/18
06:20
Downgrade
WestRock rating change  »

WestRock downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBIO

Translate Bio

$8.61

0.21 (2.50%)

06:20
12/10/18
12/10
06:20
12/10/18
06:20
Conference/Events
Translate Bio management to meet with Leerink »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

NSANY

Nissan

$0.00

(0.00%)

06:20
12/10/18
12/10
06:20
12/10/18
06:20
Periodicals
Nissan looks to block Ghosn family from Brazil apartment, FT reports »

Nissan is looking to deny…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

STMP

Stamps.com

$171.76

-4.78 (-2.71%)

06:19
12/10/18
12/10
06:19
12/10/18
06:19
Conference/Events
Stamps.com management to meet with Maxim »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$263.68

-5.98 (-2.22%)

06:17
12/10/18
12/10
06:17
12/10/18
06:17
Hot Stocks
President Trump says interviewing 'really great people' for WH Chief of Staff »

President Donald Trump…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$263.68

-5.98 (-2.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEY

KeyCorp

$16.73

-0.37 (-2.16%)

06:17
12/10/18
12/10
06:17
12/10/18
06:17
Downgrade
KeyCorp rating change  »

KeyCorp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

RF

Regions Financial

$14.90

-0.4 (-2.61%)

06:16
12/10/18
12/10
06:16
12/10/18
06:16
Downgrade
Regions Financial rating change  »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALB

Albemarle

$88.69

-2.49 (-2.73%)

06:16
12/10/18
12/10
06:16
12/10/18
06:16
Upgrade
Albemarle rating change  »

Albemarle upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CONN

Conn's

$23.74

-1.25 (-5.00%)

06:15
12/10/18
12/10
06:15
12/10/18
06:15
Upgrade
Conn's rating change  »

Conn's upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 13

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$263.68

-5.98 (-2.22%)

06:15
12/10/18
12/10
06:15
12/10/18
06:15
Hot Stocks
Pence's Chief of Staff Nick Ayers says he will depart at the end of the year »

Nick Ayers, Chief of…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$263.68

-5.98 (-2.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMO

Monarch Machine Tool Company

$0.00

(0.00%)

06:15
12/10/18
12/10
06:15
12/10/18
06:15
Conference/Events
Monarch Machine Tool Company management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

KTOS

Kratos Defense

06:15
12/10/18
12/10
06:15
12/10/18
06:15
Upgrade
Kratos Defense rating change  »

Kratos Defense upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WELL

Welltower

06:15
12/10/18
12/10
06:15
12/10/18
06:15
Initiation
Welltower initiated  »

Welltower initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

06:15
12/10/18
12/10
06:15
12/10/18
06:15
Initiation
Ventas initiated  »

Ventas initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCP

HCP

$29.87

-0.36 (-1.19%)

06:14
12/10/18
12/10
06:14
12/10/18
06:14
Initiation
HCP initiated  »

HCP initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRX

Akorn

$4.25

-1.34 (-23.97%)

06:14
12/10/18
12/10
06:14
12/10/18
06:14
Recommendations
Akorn analyst commentary  »

Piper does not view Akorn…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVTY

Tivity Health

$40.60

-0.27 (-0.66%)

, NTRI

Nutrisystem

$34.19

-1.07 (-3.03%)

06:12
12/10/18
12/10
06:12
12/10/18
06:12
Conference/Events
Tivity Health to host conference call »

Conference call to…

TVTY

Tivity Health

$40.60

-0.27 (-0.66%)

NTRI

Nutrisystem

$34.19

-1.07 (-3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

TBAKF

Ted Baker

$0.00

(0.00%)

06:11
12/10/18
12/10
06:11
12/10/18
06:11
Periodicals
Ted Baker's Ray Kelvin accused by 'hundreds' of harassment, NY Post says »

Ray Kelvin, the founder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$179.71

-4.44 (-2.41%)

, LYFT

Lyft

$0.00

(0.00%)

06:10
12/10/18
12/10
06:10
12/10/18
06:10
Periodicals
Slack hires Goldman to lead IPO, Reuters reports »

Chat provider Slack…

GS

Goldman Sachs

$179.71

-4.44 (-2.41%)

LYFT

Lyft

$0.00

(0.00%)

UBER

Uber

$0.00

(0.00%)

MSFT

Microsoft

$104.90

-4.27 (-3.91%)

GOOG

Alphabet

$1,036.52

-33.18 (-3.10%)

GOOGL

Alphabet Class A

$1,046.99

-31.41 (-2.91%)

CSCO

Cisco

$46.42

-1.96 (-4.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 10

    Jan

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.